The new UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) 2025: what has changed?
- 13 April 2026
- journal article
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (2) , 83-85
Abstract
Updates have been made to conditions with increased risk of thrombosis and use of depot medroxyprogesterone acetate (DMPA). Four medical categories—multiple risk factors for venous thromboembolism (VTE), multiple sclerosis (MS), chronic kidney disease (CKD) and sickle cell trait (SCT)—have also been added. Guidance on levonorgestrel intrauterine device (LNG-IUD) use and the risk of stroke, and consideration regarding anxiety and mood disorders and hormonal contraception (HC), feature in the 2025 UKMEC.Keywords
Funding Information
- CoSRH Clinical Effectiveness Unit (Not applicable)
This publication has 8 references indexed in Scilit:
- Contemporary Hormonal Contraception and Risk of Venous ThromboembolismJAMA, 2025
- Association of Progestogens and Venous Thromboembolism Among Women of Reproductive AgeObstetrics & Gynecology, 2022
- Contraceptive use among women with multiple sclerosis: a systematic reviewContraception, 2016
- Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic GenotypesObstetrics & Gynecology, 2014
- The risk of fracture in patients with multiple sclerosis: The UK general practice researchJournal of Bone and Mineral Research, 2011
- The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine DeviceArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Chronic kidney disease and venous thromboembolism: epidemiology and mechanismsCurrent Opinion in Pulmonary Medicine, 2009
- Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptivesContraception, 1998